lundi 1 juin 2015

Onco Actu "Spécial ASCO" du 1er juin 2015

5.5.1 ASCO (général)

ESMO Announces a Scale to Stratify the Magnitude of Clinical Benefit of Anti-Cancer Medicines [ESMO]

Advances in Treatment of Melanoma, Oral Cancer, Brain Metastases, and Childhood Cancers Presented at ASCO’s Annual Meeting [ASCO]

ASCO 2015: Abstract Thoughts On Cancer And Competition [Forbes]

Cancer drugs rankings suggest many are of little benefit to patients [The Guardian] ASCO (général) - Industriels

Clovis boasts promising ovarian cancer data as lung cancer results fade [FierceBiotech]

Genentech's PD-L1 breakthrough star 'atezo' positioned to vault ahead on cancer [FierceBiotech]

Bristol-Myers dominates--and disappoints--at ASCO immuno-oncology debut [FierceBiotech]

As ASCO Primer: Which Drug Makers are Pursuing Which Kinds of Therapies [Wall Street Journal]

5.5.10 ASCO (hémato)

Juno's Investigational CAR T Cell Product Candidate JCAR015 Demonstrates Encouraging Clinical Responses in Patients With B-Cell Cancers [Juno Therapeutics]

HELIOS: God of the sun in Greek mythology also lights the way for patients with CLL [The OBR Blog]

Roche’s Gazyva/Gazyvaro extended the time people with refractory indolent non-Hodgkin’s lymphoma lived without their disease worsening [Roche]

Astellas Annouces Preliminary Phase 1/2 Safety, Tolerability and Efficacy Data for ASP2215 in Patients With Relapsed or Refractory Acute Myeloid Leukemia [Astellas]

New Targeted Treatments for Blood Cancers Show Promise [ASCO]

AbbVie Presents Results from Phase 1 Studies of Investigational Compound Venetoclax in Patients with Multiple Myeloma at the American Society of Clinical Oncology Annual Meeting [AbbVie]

J&J multiple myeloma drug offers hope after others stop working: study [Reuters]

5.5.11 ASCO (SNC]

Celldex Builds Case for Brain Cancer Vaccine With New ASCO Data [Xconomy]

Study Questions Use of Whole-Brain Radiation to Treat Cancer [Wall Street Journal]

Celldex vaccine helps brain cancer patients live longer: study [Reuters]

5.5.12 ASCO (médico-éco)

Bristol-Myers Squibb Has A Cancer Breakthrough. Here's Why It Should Cut The Price [Forbes]

High Drug Prices Attacked at Meeting [Wall Street Journal]

5.5.13 ASCO (divers)

Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting [Myriad]

Studies Offer Improved Treatments for Diverse Set of Common and Rare Cancers [ASCO]

Acelarin cancer drug impact hope 'remarkable' [BBC News]

Myriad Presents New myRisk(TM) Hereditary Cancer Data at 2015 ASCO Annual Meeting [Myriad]

Obesity poised to overtake smoking as key cause of cancer [The Telegraph]

5.5.2 ASCO (sein)

Pfizer Announces Palbociclib More Than Doubled Progression-Free Survival in Phase 3 Trial for Patients With HR+, HER2- Metastatic Breast Cancer Whose Disease Has Progressed Following Endocrine Therapy [Pfizer]

Roche’s Perjeta regimen helped people with HER2-positive early breast cancer live longer without their disease returning or getting worse compared to Herceptin and chemotherapy [Roche]

Pfizer's Ibrance drug slows progression of breast cancer [Reuters]

Some older breast cancer patients may skip invasive biopsy [Reuters]

5.5.4 ASCO (immunothérapies)

ASCO '15: Merck, Bristol Drugs Boost Immune System to Kill Broad Swath of Cancer Types [TheStreet]

Father Knows Best As Immunotherapy Takes Its Place As A Pillar Of Cancer Care [Dr Len]

New Immunotherapies for Multiple Hard-to-Treat Cancers [ASCO]

First Study Evaluating DNA Mismatch Repair as Genetic Guide for Immunotherapy Treatment with Merck’s KEYTRUDA® (pembrolizumab) Presented at 2015 ASCO Annual Meeting and Published in the New England Journal of Medicine [Merck]

Together, Genetic Test And Drug Unleash Immune System Against Tumors [Forbes]

Scientists hail 'new era' for cancer treatment [The Guardian]

'Cure for terminal cancer' found in game-changing drugs [The Telegraph]

Doctors Seek Test for Deploying New Life-Extending Cancer Drugs [NY Times]

Merck immunotherapy appears effective in head and neck cancer-study [Reuters]

New Class of Drugs Shows More Promise in Treating Cancer [NY Times]

Genetic glitch can predict response to new class of cancer drugs [Reuters]

5.5.5 ASCO (gastro-intestinal)

Glass 'bullets' offer a shot at beating bowel cancer [The Telegraph]

5.5.6 ASCO (peau)

Dual checkpoint blockade in metastatic melanoma: PFS makes a strong case, but overall survival impact still an unknown [The OBR Blog]

Updated Positive Results from Two Trials of Cobimetinib in Combination with Vemurafenib for the Treatment of Patients with Advanced Melanoma Presented at 2015 ASCO Annual Meeting [Exelixis]

Cancer Drug Combination Is Potent, in Response and Side Effects [Bloomber]

Phase III CheckMate -067 Trial Demonstrates Superior Progression-Free Survival of Opdivo+Yervoy Regimen or Opdivo Monotherapy vs. Yervoy Monotherapy in Previously Untreated Patients with Advanced Melanoma [BMS]

Updated data showed Roche’s investigational combination of cobimetinib and Zelboraf (vemurafenib) helps people with advanced melanoma live for a year without their disease worsening [Roche]

Cancer drug combination 'shrinks 60% of melanomas' [BBC News]

Combination of Novartis drugs Tafinlar® and Mekinist® shows significant survival benefit in patients with metastatic melanoma [Novartis]

Study: Pair of Bristol-Myers Drugs Sees Success in Battling Skin Cancer [Wall Street Journal]

5.5.8 ASCO (poumon)

Exelixis Announces Positive Results from Phase 2 Trial of Cabozantinib in Patients with EGFR Wild-Type Non-Small Cell Lung Cancer [Exelixis]

Exelixis Announces Positive Results from Phase 2 Investigator-Sponsored Trial of Cabozantinib in RET-Rearranged Non-Small Cell Lung Cancers [Exelixis]

CheckMate? The rules of the game may be changing [The OBR Blog]

Opdivo (nivolumab) Demonstrates Superior Survival Compared to Standard of Care (docetaxel) for Previously-Treated Squamous Non-Small Cell Lung Cancer in Phase III Trial [BMS]

Lung cancer therapy is 'milestone' [BBC News]

ASCO 2015: Superior overall survival for afatinib compared to erlotinib demonstrated in head-to-head trial in patients with previously treated advanced squamous cell carcinoma of the lung [Boehringer Ingelheim]

Bristol's Opdivo cuts risk of lung cancer death for some [Reuters]

5.5.9 ASCO (autres organes)

Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers Squibb’s PD-1 Immune Checkpoint Inhibitor is First to Demonstrate Anti-Tumor Activity In Patients With Hepatocellular Carcinoma [BMS]

New Findings Show Durable Anti-Tumor Activity with KEYTRUDA® (pembrolizumab), Merck’s Anti-PD-1 Therapy, in Patients with Advanced Head and Neck Cancer, Regardless of PD-L1 Expression Status [Merck]

Eisai drug extends survival in patients with rare cancers [Reuters]